EVAR术后1a型内漏不同治疗方式的系统评价与Meta分析
该系统评价与Meta分析纳入39项非随机研究共714例患者,评估EVAR术后持续性或迟发性1a型内漏的多种治疗方式。总体技术成功率93.2%,临床成功率88.2%,30天死亡率3.2%,开放手术死亡率较高(6.6%)。结论认为修复总体可行,治疗选择应基于内漏特征、主动脉解剖和患者手术风险。
要点
- 总体技术成功率93.2%,临床成功率88.2%,30天死亡率3.2%。
- 近端延伸技术成功率最高(98.1%),内锚定最低(57.2%)。
- 开放手术30天死亡率6.6%,高于总体水平。
核心结论
- EVAR术后1a型内漏修复总体可行,早中期结果良好。
- 治疗选择应基于内漏特征、主动脉解剖和患者手术风险。
- 保守治疗和栓塞仅考虑用于低流量内漏和不适合手术的患者。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Web of Science、Scopus和Cochrane Library至2018年8月。
- 纳入39项非随机研究,共714例患者(男性88.1%,95%CI 84.5-91.7;加权平均年龄75.76岁,95%CI 74.11-77.4)。
- 纳入标准为EVAR术后1a型内漏治疗研究(排除首次EVAR术中治疗),样本量≥5例且可提取结局数据。
- 采用随机效应模型进行比例Meta分析。
主要发现
- 总体估计技术成功率为93.2%(95%CI 90.5-95.8),临床成功率为88.2%(95%CI 84.5-91.9)。
- 近端延伸技术成功率98.1%(95%CI 96.3-99.8),烟囱EVAR为93.9%(95%CI 89.9-97.9),开窗EVAR为86.2%(95%CI 77.3-95.1)。
- 开放转换技术成功率96.5%(95%CI 93-100),栓塞为95.2%(95%CI 90.4-100),内锚定为57.2%(95%CI 14.1-100)。
- 保守治疗临床成功率75.4%(95%CI 56.4-94.5)。
- 总体估计30天死亡率为3.2%(95%CI 1.7-4.7),开放手术患者较高(6.6%,95%CI 1.7-11.5)。
临床怎么用
- 对于EVAR术后1a型内漏,近端延伸、烟囱EVAR、开窗EVAR、开放转换和栓塞均可作为治疗选项。
- 选择治疗方式时应综合考虑内漏特征、主动脉解剖和患者手术风险。
- 保守治疗和栓塞应仅用于经过选择的病例,如低流量内漏和不适合手术的患者。
局限性
- 纳入研究均为非随机研究,存在选择偏倚和异质性可能。
- 部分治疗方式的样本量较小,如内锚定仅35例,结果置信区间宽。
- 随访时间平均19.4个月,缺乏长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insufficient evidence is available to recommend a particular strategy for the treatment of type 1a endoleaks (T1aELs) after endovascular abdominal aneurysm repair (EVAR). The aim of this study was to report outcomes of the different treatment modalities proposed for persistent and late-occurring T1aEL after EVAR. METHODS: A systematic review of the literature (database searched: PubMed, Web of Science, Scopus, Cochrane Library) was undertaken until August 2018. Studies about treatment of T1aEL after EVAR (excluding intraoperative treatments during the first EVAR) presenting a series of 5 or more patients with extractable outcome data (at least intraoperative and/or early results) were included. Meta-analyses of proportions were performed using a random-effects model. RESULTS: A total of 39 nonrandomized studies were included (714 patients; 88.1% males, 95% confidence interval [CI] 84.5-91.7; weighted mean age 75.76 years, 95% CI 74.11-77.4). Overall estimated technical success (TS) and clinical success (CS) rates were 93.2% (95% CI 90.5-95.8) and 88.2% (95% CI 84.5-91.9), respectively. Two hundred eighteen patients underwent proximal extension (98.1% TS, 95% CI 96.3-99.8), 131 chimney EVAR (93.9% TS, 95% CI 89.9-97.9), 97 fenestrated EVAR (86.2% TS, 95% CI 77.3-95.1), 90 open conversion (96.5% TS, 95% CI 93-100), 71 embolization (95.2% TS, 95% CI 90.4-100), 35 endostapling (57.2% TS, 95% CI 14.1-100), and 72 conservative treatment (75.4% CS, 95% CI 56.4-94.5). Estimated overall 30-day mortality was 3.2% (95% CI 1.7-4.7), and it was higher for patients undergoing open surgery (6.6%, 95% CI 1.7-11.5). Overall, endoleak resolution during the mean follow-up of 19.4 months (95% CI 15.45-23.36) was maintained in 91% of the patients (95% CI 87.7-94.3). CONCLUSIONS: T1aEL repair appeared generally feasible, with good early to midterm outcomes. Different treatments are available, and the choice should be based on endoleak characteristics, aortic anatomy, and the patient's surgical risk. Conservative treatment and endoleak embolization should be considered only in selected cases, such as low-flow endoleaks and unfit patients.
引用
- Perini P, Bianchini Massoni C, Mariani E, et al. Systematic Review and Meta-Analysis of the Outcome of Different Treatments for Type 1a Endoleak After EVAR. Ann Vasc Surg. 2019. PMID: 31200054. doi:10.1016/j.avsg.2019.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。